
Last updated: 2026-10-29 · Written by: SaiyanMed Research Team · Reading time: about 20 minutes
Quick answer: BPC-157 acetate and BPC-157 arginate are the same 15-residue peptide, GEPPPGKPADDAGLV (C62H98N16O22, about 1419.6 g/mol). Only the counter-ion in the solid differs.[1][4] Every ‘arginate is more stable’ number traces back to one manufacturer’s patent family.[1][2] That patent shows a large advantage for the arginine salt in heat stress and in simulated gastric fluid at pH 3–4. It shows almost no advantage at pH 2. The sodium salt captures much of the same benefit, and nobody has independently replicated the work. Our own calculations below suggest that a good part of the gap may be a pH effect rather than a property of arginine. The arginate also carries less peptide per milligram: about 80% for an ideal 1:2 salt versus about 96% for the registered mono-acetate (our calculation).
Key takeaways
- Same molecule, different salt. Mass spectrometry of either form shows the same peptide ion (the patent reports m/z 1419.8 for [M+H]+).[1]
- The registered acetate is a mono-acetate. FDA’s GSRS lists BPC-157 acetate as C62H98N16O22·C2H4O2, MW 1479.59.[4] Many web pages assume a di-acetate. Real lots vary, so measure rather than assume.
- One source, no replication. All acetate-versus-arginate stability data come from Diagen’s WO2014142764A1 / US 9,850,282 B2. The tables have no replicates, no error bars and no degradant identification.[1][2]
- The pH confound is quantitative, not hypothetical. In the water test the acetate started at pH 3.88 and the arginate at pH 7.35. In the gastric test, a 2 mg/mL arginate sample carries about 2.3 mM of base. That is more than the free acid at nominal pH 3 (1 mM) or pH 4 (0.1 mM), and the patent does not report the pH after the sample was added (our calculation).[1]
- Stability is not bioavailability. No study has compared absorption of the acetate and arginate forms. The only published pharmacokinetics are for injected peptide in rats and dogs, and an oral formulation patent tested the arginate alone.[10][11]
- Verify, don’t trust the label. Salt form is shown by counter-ion assays (ion chromatography, amino acid analysis, NMR), not by HPLC purity or intact mass alone.
Contents
- The chemistry: where each counter-ion binds
- Stoichiometry and peptide content, worked out
- Where the arginate claim comes from
- How the patent makes the arginine salt
- The stability data in full
- Critical appraisal
- What has actually been measured in living systems
- How to verify salt form analytically
- Reading a COA for salt form
- Myths versus evidence
- Glossary
- FAQ
The chemistry: where each counter-ion binds
Synthetic peptides are almost never isolated as neutral molecules. Their charged groups pair with oppositely charged ions from the final purification or exchange step. Solid-phase synthesis and reversed-phase HPLC use trifluoroacetic acid (TFA), so crude peptides usually emerge as TFA salts. They are then often exchanged to acetate or chloride.[5] The counter-ion is part of the solid material, not of the amino-acid sequence.
BPC-157 is unusual because it is an acidic peptide. Counting ionisable groups in GEPPPGKPADDAGLV:
| Group | Position | Typical pKa range (textbook) | Charge near pH 7 | Pairs with |
|---|---|---|---|---|
| α-amino (N-terminus) | Gly1 | ≈ 8–9 | +1 | Acetate, TFA, chloride (anions) |
| ε-amino | Lys7 | ≈ 10–10.5 | +1 | Acetate, TFA, chloride |
| γ-carboxyl | Glu2 | ≈ 4.1–4.3 | −1 | Na⁺, protonated arginine, lysine or ornithine (cations) |
| β-carboxyl | Asp10 | ≈ 3.7–3.9 | −1 | Cations |
| β-carboxyl | Asp11 | ≈ 3.7–3.9 | −1 | Cations |
| α-carboxyl (C-terminus) | Val15 | ≈ 2–3.5 | −1 | Cations |
Two practical consequences follow. First, an acetate salt pairs acetate with the two basic sites, so at most two acetates are expected. Second, a basic amino acid salt pairs a protonated arginine (guanidinium, about +1 at any relevant pH) with the four carboxylates. Diagen’s patent therefore claims 1:1, 1:2 and 1:3 peptide-to-base ratios and prefers the 1:2 di-L-arginine salt, which it calls ‘Arg-BPC’.[1] Dissolve the acetate in water and you get an acidic solution (the patent measured pH 3.88 at 1 g/100 mL). The 1:2 arginine salt was made at pH 7.40, and its solution measured pH 7.35.[1] That difference becomes central later.
Stoichiometry and peptide content, worked out
A vial labelled 5 mg normally contains 5 mg of powder: peptide plus counter-ions, water and minor impurities. Counter-ion content must be accounted for whenever peptide quantity matters.[5] For glucagon, metrologists assigned the true peptide mass fraction only after separately measuring TFA, water, inorganic ions and related impurities.[6] Here are the ideal-stoichiometry numbers for BPC-157. All salt MWs and fractions below are SaiyanMed calculations using standard atomic weights (C 12.011, H 1.008, N 14.007, O 15.999). They ignore water and residual ions.
| Form | Composition | Salt MW (calc.) | Peptide fraction (calc.) | Peptide in 10 mg powder (calc.) | Status |
|---|---|---|---|---|---|
| Free peptide | C62H98N16O22 | 1419.6 | 100% | 10.00 mg | Reference |
| Mono-acetate | Peptide · 1 CH3COOH | 1479.6 | 95.9% | 9.59 mg | GSRS-registered form (MW 1479.59)[4] |
| Di-acetate | Peptide · 2 CH3COOH | 1539.7 | 92.2% | 9.22 mg | Chemically plausible maximum (2 basic sites) |
| Mono-TFA | Peptide · 1 CF3COOH | 1533.6 | 92.6% | 9.26 mg | Common crude form |
| Di-TFA | Peptide · 2 CF3COOH | 1647.6 | 86.2% | 8.62 mg | Common crude form |
| Disodium | 2 H replaced by Na | 1463.5 | 97.0% | 9.70 mg | Stoichiometry not stated in the patent |
| 1:1 arginine | Peptide · 1 Arg | 1593.8 | 89.1% | 8.91 mg | Patent Example 2 |
| 1:2 arginine (Arg-BPC) | Peptide · 2 Arg | 1768.0 | 80.3% | 8.03 mg | Patent’s preferred form |
| 1:2 ornithine | Peptide · 2 Orn | 1683.9 | 84.3% | 8.43 mg | Patent Example 5 |
| 1:3 lysine | Peptide · 3 Lys | 1858.1 | 76.4% | 7.64 mg | Patent Example 4 |

Worked example: comparing two vials fairly
Suppose two vials are each labelled 10 mg, one an ideal mono-acetate and one an ideal 1:2 arginate. From the table, they hold about 9.59 mg and 8.03 mg of peptide. The acetate therefore holds about 19% more peptide (9.59 ÷ 8.03 ≈ 1.19). In moles that is 6.76 µmol versus 5.66 µmol. Add a typical 5% water content to both and the absolute numbers fall further, but the ratio barely moves. Any laboratory comparison between the two forms should normalise on molar peptide concentration, ideally from a measured net peptide content. Normalising on powder weight is not enough. None of the stability tables discussed below say which basis was used.
Where the arginate claim comes from
| Document | Owner / inventors | Key dates | What it adds |
|---|---|---|---|
| US 6,288,028 B1[3] | Sikirić P. et al. | Granted 2001-09-11 | Earlier BPC salts. Diagen later describes these as ‘prone to polar degradation product up to 10%’.[1] |
| WO2014142764A1[1] | Diagen d.o.o.; R. Ručman | Priority 2013-03-13; published 2014-09-18 | Basic-amino-acid salts (Arg, Lys, Orn; L, D or DL); Examples 1–5; stability Tables 1–6 |
| US 9,850,282 B2[2] | Diagen d.o.o. | Filed 2013-05-09; granted 2017-12-26 | Granted claim 1 is narrower: peptide · 2 basic amino acids |
| EP4226918A1[11] | F. Majewski (individual) | Priority 2022-02-15; published 2023-08-16 | Oral capsule-in-capsule formulation tested with Arg-BPC-157 only; no acetate comparator |
Two details are rarely reported. First, the granted US claim covers only the 1:2 salt with a basic amino acid. That is narrower than the WO application’s 1:1 to 1:3 range.[1][2] Second, the ‘stable BPC’ marketing language borrows the phrase ‘stable gastric pentadecapeptide’ from Sikirić’s academic papers.[7] Those papers describe the peptide as stable in gastric juice, without any arginine salt. ‘Pentadeca arginate’ (PDA) is a trade name with no INN or GSRS entry that we could find. Pages selling it variously describe it as Arg-BPC or as a modified sequence, so the name alone does not identify a substance.
How the patent makes the arginine salt
The process, condensed from Examples 1–5 of WO2014142764A1:[1]
- Dissolve BPC-157 acetate or TFA salt in water.
- Add an excess of the basic amino acid. In Example 3, 420 mg L-arginine (2.41 mmol) was added to 1.00 g acetate (stated as 0.705 mmol), about 3.4 equivalents, in 4 mL water. The solution measured pH 8.92.
- Back-titrate with diluted acetic acid (50%) to pH 7.40 ± 0.05 for 1:2 salts, or 4.60 ± 0.05 for 1:1 salts.
- Freeze-dry, then purify on a C18 column with water and 0–5% isopropanol. No acid modifier is used. Discard the early fractions (‘salts and impurities’) and freeze-dry the main fraction.
- Confirm by amino acid analysis (e.g. ‘2-Arg’ per peptide), TOF MS (m/z 1419.8 peptide + H+; 175.1 arginine + H+), FTIR, UV, optical rotation and HPLC purity (99.48–99.54%).
What the process tells a careful reader
- Acetate is added back on purpose. The pH adjustment uses acetic acid, so the solution before purification contains acetate, arginine and peptide together. The patent relies on chromatography to separate them and confirms arginine by amino acid analysis. It reports no acetate assay of the final product. A residual mixed acetate/arginate cannot be excluded from the text.
- The mole bookkeeping is inconsistent. Example 3 treats 1.00 g of acetate as 0.705 mmol, which implies about 1418 g/mol, the free-peptide mass with no acetate at all. Examples 1 and 5 treat 500 mg of TFA salt and of acetate as the same 0.34 mmol, which implies about 1470 g/mol. A real di-TFA salt would be 1647.6 g/mol (our calculation). The equivalents of arginine actually used are therefore only approximate.
- Yields are plausible but not diagnostic. On the patent’s own mole figure, 1.10 g from Example 3 is about 88% of a theoretical 1.246 g of 1:2 salt. If the starting material was a true mono-acetate, the figure is about 92% of 1.195 g (our calculation).
- A probable chloride source. Example 5 lists ‘L-ornithine 1.77 mg, 1.05 mmol’. The milligram figure must be a typo. 177 mg ÷ 1.05 mmol ≈ 168.6 g/mol matches ornithine monohydrochloride, not free ornithine (132.2 g/mol). That would introduce chloride into that preparation (our inference).
- Optical rotation can tell D- from L-arginine salts. Example 1 (D-Arg) reports [α]D −154°; Example 3 (L-Arg) reports −124.3°. The difference is consistent with the counter-ion’s own rotation adding in opposite directions. It is a useful identity check for which enantiomer of arginine is present.
The stability data in full
Every value below is transcribed from WO2014142764A1.[1] Peptide content was measured by HPLC: Reprosil C18, 250 × 4.6 mm, 5 µm; mobile phase A 0.1% TFA / 5% acetonitrile; B 0.1% TFA / 40% acetonitrile; 100% to 30% A over 25 min; 1.5 mL/min; 20 °C; UV 210 nm. The patent does not state replicate numbers, standard deviations, sample normalisation basis, or degradant identities.
Table 1. Solid state, 50 °C / 65% relative humidity
| Salt | Day 0 | Day 10 | Day 30 | Day 60 | Day 90 |
|---|---|---|---|---|---|
| Acetate | 99.65 | 95.97 | 91.98 | 85.49 | 85.90 |
| Sodium salt | 99.20 | 97.22 | 96.46 | 97.38 | 97.14 |
| Arg-BPC (1:2) | 99.46 | 99.29 | 99.20 | 98.96 | 99.07 |
| Arg-BPC + NaHCO3 | 99.46 | 99.37 | 99.29 | 99.16 | 99.15 |
| Lys salt | 99.47 | 99.24 | 99.27 | 98.90 | 99.28 |
Table 2. Aqueous solution, 1 g/100 mL, 50 °C
| Salt (starting pH) | 0 h | 20 h | 65 h | 148 h | 388 h |
|---|---|---|---|---|---|
| Acetate (3.88) | 98.89 | 71.17 | 55.25 | 52.55 | 21.30 |
| Sodium salt (8.42) | 99.01 | 98.36 | 97.47 | n.d. | 96.74 |
| Arg-BPC (7.35) | 99.05 | 98.97 | 99.04 | 99.10 | 99.01 |
| Lys salt (7.28) | 99.07 | 99.40 | 99.09 | 99.35 | 99.01 |
| Orn salt (7.12) | 100.00 | 99.64 | 99.78 | 99.59 | 99.44 |
Table 3. Aqueous solution, 100 °C for 1 hour
| Salt | Before | After 1 h |
|---|---|---|
| Acetate | 98.89 | 56.80 |
| Sodium salt | 99.01 | 98.56 |
| Arg-BPC | 99.05 | 99.08 (patent: ‘unchanged!’) |
Tables 4–6. Artificial gastric juice with pepsin, 37 °C
The medium is 0.08 mol HCl, 0.03 mol NaCl and 1.0 g pepsin per litre. Samples were 10 mg salt per 5 mL, incubated at pH 2.0, 3.0 and 4.0. Values are percent of the starting amount. The patent heads these tables ‘content decrement’, but the numbers start at 100 and fall, so they read as percent remaining.
| pH 2.0 | 0 h | 0.5 h | 1 h | 1.5 h | 2 h | 2.5 h |
|---|---|---|---|---|---|---|
| Acetate | 100 | 21.4 | 8.2 | 4.75 | 2.46 | 2.1 |
| Sodium salt | 100 | 21.6 | 6.7 | 4.4 | 4.2 | 2.7 |
| Arg-BPC | 100 | 30.2 | 13.5 | 8.2 | 6.0 | 4.9 |
| pH 3.0 | 0 h | 0.5 h | 1 h | 2 h | 3 h | 4 h | 5 h |
|---|---|---|---|---|---|---|---|
| Acetate | 100 | 41.7 | 26.1 | 7.8 | 2.5 | 1.1 | 0.08 |
| Sodium salt | 100 | 81.9 | 71.6 | 56.0 | 40.2 | 29.7 | 10.1 |
| Arg-BPC | 100 | 98.1 | 96.5 | 93.6 | 90.0 | 87.2 | 84.9 |
| pH 4.0 | 0 h | 1 h | 2 h | 3 h | 4 h | 5 h | 6 h | 7 h | 8 h |
|---|---|---|---|---|---|---|---|---|---|
| Acetate | 100 | 89.7 | 81.3 | 72.5 | 60.9 | 56.4 | 48.8 | 44.6 | 38.0 |
| Sodium salt | 100 | 99.0 | 98.9 | 94.6 | 89.7 | 78.3 | 76.3 | 68.2 | 60.9 |
| Arg-BPC | 100 | 99.9 | 99.5 | 98.7 | 96.1 | 89.8 | 84.6 | 73.5 | 67.2 |

The patent also reports UV-light and formulation tests. In Example 16, tablets of the arginine salt held for 18 months retained 99.8% at −15 °C, 96.6% at 25 °C and 92.35% at 50 °C. There is no acetate comparator. The patent states that the peptide is most stable at pH 6.5–8.5 and suggests NaHCO3 or mannitol as stabilisers.[1]
Critical appraisal
1. In water, the counter-ion sets the pH
Table 2 is unbuffered. The acetate solution started at pH 3.88; the arginine, lysine, ornithine and sodium solutions started between 7.12 and 8.42. The patent itself names pH 6.5–8.5 as the peptide’s most stable range.[1] Every non-acetate salt in Table 2 sat inside that window, and the acetate sat well outside it. The table is therefore best read as ‘BPC-157 at pH 3.9 versus BPC-157 at pH 7–8’. The pH was set by the counter-ion. The data don’t show that arginine stabilises the peptide at equal pH, because that experiment was not done. An acetate solution adjusted to pH 7.4 with a non-amino-acid buffer is the missing control. The same logic applies to Table 3 at 100 °C.
2. In the gastric test, the sample can move the pH
This is the point no other analysis we found has worked through. Pepsin activity depends strongly on pH. It is most active around pH 2 and much less active as the pH rises toward 4–5.[12] The patent’s medium is plain HCl/NaCl with no buffer. As written (0.08 mol HCl per litre), it would sit near pH 1.1, and the patent does not say how the pH 2, 3 and 4 media were prepared. Now consider what the sample adds (our calculation):
| Quantity | Value (calc.) |
|---|---|
| Sample concentration | 10 mg / 5 mL = 2 mg/mL |
| 1:2 arginate: peptide | 2 ÷ 1768.0 ≈ 1.13 mM |
| 1:2 arginate: arginine (base equivalents carried in) | ≈ 2.26 mM |
| Mono-acetate: peptide (no net added base) | 2 ÷ 1479.6 ≈ 1.35 mM |
| Free H⁺ at nominal pH 2 / 3 / 4 | 10 mM / 1 mM / 0.1 mM |
In the arginate salt, the peptide’s carboxyl groups arrive already deprotonated, balanced by arginine. Dissolving it in acid therefore consumes roughly 2 mM of H⁺. At nominal pH 2 that is a fraction of the 10 mM free acid, so the pH barely moves, and Table 4 indeed shows almost no salt effect. At nominal pH 3, 2.26 mM of base exceeds the 1 mM of free acid. Unless the medium was re-adjusted after adding the sample, the arginate incubation would drift toward a higher pH where pepsin works more slowly. The sodium salt also carries base, and in Table 5 it sits between acetate and arginate. The acetate carries essentially none. This is the ordering a pH-drift explanation predicts. It does not prove the explanation, but the patent’s tables cannot rule it out. A single sentence reporting final pH, or the use of a buffered medium, would have settled it.
3. The assay measures peptide, not salt, and only as a percentage
- The HPLC uses 0.1% TFA in both mobile phases. On the column every sample behaves as a TFA ion pair, so the method quantifies the peptide peak, not the counter-ion. That is appropriate, but it means the stability tables never confirm which salt was actually present.
- Solid- and solution-state values (about 99.5 at day 0) look like chromatographic area-percent purity, not assay against a reference standard. Area percent cannot detect loss to adsorption, aggregation or species that don’t absorb at 210 nm. The gastric tables are normalised to 100 at t = 0, a third basis again.
- There are no replicates, standard deviations or system-suitability data, and no mass balance. The non-monotonic rows in Table 1 suggest assay variability of roughly ±1 percentage point.
- Degradants are not identified. Without knowing whether loss is hydrolysis at Asp residues, pepsin cleavage or something else, we can’t link the effect to a mechanism.
4. The sodium salt does most of the work in the solid state
At day 90 at 50 °C, the sodium salt retained 97.14% against 99.07% for Arg-BPC and 85.90% for acetate.[1] Moving away from acetate recovers about 11 of the 13 points; arginine adds about 2 more, inside likely assay noise. Lysine and ornithine perform like arginine. That pattern fits a ‘basic counter-ion, higher micro-environmental pH’ explanation better than anything specific to arginine.
5. The literature disagrees with itself
Sikirić’s group has described BPC-157 since the 1990s as ‘stable in human gastric juice for more than 24 h’, citing work by Veljača and colleagues. The statement is repeated in reviews to 2025.[7][8][9] Diagen’s own tables show acetate losing most of its peptide within an hour at pH 2–3.[1] Several things differ between the two: natural versus artificial juice, pepsin activity, assay and starting salt. The underlying gastric-juice data were never published in full, so the conflict cannot be resolved from public sources. An honest article has to report both claims and say they are unreconciled.
6. Who generated the data
The comparison was run by the company that patented the arginine salts. Patents are not peer-reviewed, and we found no independent laboratory study that repeats the acetate-versus-arginate comparison under controlled pH. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies, of which 35 were preclinical and 1 clinical, which shows how thin the human evidence base is in general.[14]
Evidence grade
| Claim | What supports it | Our grade |
|---|---|---|
| Acetate and arginate share the same peptide | MS and amino acid analysis in the patent; GSRS structure[1][4] | Strong |
| Arginate retains more peptide than acetate in unbuffered water and heat | Patent Tables 2–3, single source, pH-confounded[1] | Weak–moderate |
| Arginate retains more peptide in the solid state at 50 °C | Patent Table 1; sodium salt close behind[1] | Weak–moderate |
| Arginate resists pepsin at pH 3–4 | Patent Tables 5–6; final pH unreported[1] | Weak |
| Arginate resists stomach acid at pH 2 | Contradicted by patent Table 4[1] | Not supported |
| Arginate has higher oral bioavailability than acetate | No comparative data exist | No evidence |
What has actually been measured in living systems
Readers often move from ‘more stable in a test tube’ to ‘better absorbed’. The published record does not support that step:
- He et al. 2022 measured pharmacokinetics of BPC-157 given by injection to rats and dogs, using LC-MS/MS. They reported intramuscular bioavailability of about 14–19% in rats and 45–51% in dogs, and a short plasma half-life (under 30 min). There was no oral arm and no salt comparison.[10]
- EP4226918A1 describes an oral capsule-in-capsule formulation with an absorption enhancer and an organic acid. It reports plasma concentrations of Arg-BPC-157 at 60–120 minutes in the pg/mL range, higher than simple enteric capsules of the same peptide. Only the arginine salt was tested. There is no acetate arm and no intravenous reference, so the document supports no salt comparison and no bioavailability percentage.[11]
- Figures such as ‘90% oral bioavailability’ or ‘7× better absorption’ appear on vendor pages without a traceable primary source. We could not find one.
How to verify salt form analytically
No single technique on a typical certificate of analysis (COA) establishes salt form. Here is what each method can and cannot tell you.
| Technique | What it shows | What it cannot show | Salt-form relevance |
|---|---|---|---|
| RP-HPLC (UV 210–220 nm) | Chromatographic purity of the peptide | Counter-ion identity; with a TFA mobile phase every salt looks the same | None directly |
| ESI or MALDI mass spectrometry | Peptide identity ([M+H]+ ≈ 1419.8; [M+2H]2+ ≈ 710.4) | The ions dissociate in the source, so the intact salt is not observed | Indirect: an m/z 175.1 peak shows arginine is present, not how much |
| Amino acid analysis (AAA) | Residue ratios; extra Arg (BPC-157 contains none) reveals arginine counter-ion stoichiometry; also gives net peptide content | Acetate or TFA | High for arginate |
| Ion chromatography / HPLC-CAD | Acetate, TFA, chloride, sodium quantitatively | Peptide identity | High for acetate and residual TFA/Cl |
| 1H NMR | Acetate methyl singlet near 1.9 ppm; arginine δ-CH2 signals; molar ratios against peptide signals | Trace levels | High |
| 19F NMR | Residual TFA | Non-fluorinated ions | High for TFA |
| Karl Fischer titration | Water content | Ions | Needed for mass balance |
| CHN elemental analysis / nitrogen | Total N, used to compute net peptide content | Which ion | Moderate |
| Specific optical rotation | Batch consistency; D- versus L-arginine counter-ion (patent: −154° vs −124.3°)[1] | Stoichiometry on its own | Moderate |
| pH of a 1% solution | Acetate ≈ 3.9 vs 1:2 arginate ≈ 7.4 (patent values)[1] | Exact composition | A quick screen |
A complete, mass-balanced description of a lot looks like this. Peptide content (AAA or nitrogen) + counter-ion content (IC or NMR) + water (Karl Fischer) + related impurities (HPLC) should sum to about 100%. This is the approach metrology institutes use for peptide reference materials.[6]
Reading a COA for salt form
- Is the salt named with stoichiometry? ‘BPC-157 acetate’ should ideally give a formula or MW (e.g. 1479.6 for mono-acetate). ‘Arginate’ should say 1:1 or 1:2.
- Is net peptide content reported, and by what method? Without it, purity alone tells you nothing about how much peptide a labelled milligram contains.
- Is there a counter-ion assay? Look for ion chromatography, NMR or AAA results. A COA showing only HPLC purity and MS identity has not established the salt form.
- Is residual TFA addressed? An exchanged acetate or arginate may still carry TFA from synthesis.
- Does the MS section stay modest? It should claim identity of the peptide, not of the salt.
- Is water content stated? Lyophilised peptides are hygroscopic, and several percent water is common.
- Does a ‘pentadeca arginate’ product state its sequence? If the sequence differs from GEPPPGKPADDAGLV, it is a different molecule, not a salt form.
For more on interpreting each COA section, see our guides to reading a peptide COA and what mass spectrometry can and cannot confirm.
Myths versus evidence
| Claim seen online | What the evidence shows |
|---|---|
| ‘Arginate is a different, improved peptide’ | Same sequence and same peptide mass; only the counter-ion differs.[1][4] |
| ‘1000× more stable’ | Not stated in the patent. It comes from dividing 84.9% by 0.08% in one pH 3 time point, and that comparison is likely pH-confounded. |
| ‘95% versus 2% in stomach acid’ | At pH 2 the patent shows 4.9% versus 2.1% at 2.5 h. Both forms were essentially destroyed.[1] |
| ‘Arginate survives the stomach’ | Only shown at pH 3–4 in an unbuffered simulated medium. |
| ‘90% oral bioavailability’ / ‘7× better absorption’ | No traceable primary source. No comparative absorption study exists. |
| ‘Nobody has ever measured BPC-157 in blood after oral dosing’ | EP4226918A1 reports plasma levels from an oral Arg-BPC formulation, but without a salt comparison or IV reference.[11] |
| ‘Arginine is a standard stabilising excipient, so it must help’ | Arginine is used as an excipient in some protein formulations, but that says nothing specific about BPC-157. The patent’s own sodium salt performs nearly as well.[1] |
| ‘The patent came from the University of Zagreb group’ | The 2013 basic-amino-acid salt patents belong to Diagen d.o.o.; Sikirić’s group holds the earlier 1990s salt patent.[1][3] |
| ‘pH 7.4 proves better oral stability’ | 7.40 is the pH at which the 1:2 salt is prepared, not a test condition.[1] |
| ‘A 5 mg arginate vial equals a 5 mg acetate vial’ | An ideal 1:2 arginate holds about 16% less peptide than an ideal mono-acetate by mass (80.3% vs 95.9%, our calculation). |
Glossary
| Term | Meaning |
|---|---|
| Counter-ion | An ion of opposite charge that balances charged groups on a peptide in its solid form (e.g. acetate, TFA, chloride, sodium, protonated arginine). |
| Salt form | The specific combination of peptide and counter-ion(s), including their ratio (stoichiometry). |
| Stoichiometry | The molar ratio of counter-ion to peptide, e.g. 1:2 for di-arginine. |
| Net peptide content (NPC) | The fraction of powder mass that is peptide, after counter-ions, water and impurities. Usually measured by AAA or nitrogen. |
| HPLC purity | The peptide peak’s share of total peak area at a given wavelength. It is not the same as content. |
| Arg-BPC | Patent abbreviation for the 1:2 BPC-157 di-L-arginine salt. |
| Pentadeca arginate (PDA) | A trade name with no registry definition. Check the stated sequence and salt. |
| GSRS | FDA’s Global Substance Registration System, which defines substances by structure, including salts. |
| Simulated gastric fluid | A laboratory acid/pepsin mixture used as a stomach model. It is not a measure of absorption. |
| Bioavailability | The fraction of a dose reaching systemic circulation, measured against an intravenous reference. |
| Ion chromatography (IC) | A method that separates and quantifies small ions such as acetate, chloride, TFA and sodium. |
| Karl Fischer titration | The standard method for measuring water content in a solid. |
Frequently asked questions
Is BPC-157 arginate better than BPC-157 acetate?
For chemical stability in unbuffered water, heat and pH 3–4 simulated gastric fluid, the only available data, a manufacturer’s patent, favour the arginine salt. Much of that advantage may come from the higher pH the arginine salt produces in solution. The sodium salt does nearly as well, and at pH 2 no form survived. There is no comparative evidence on absorption or biological effect. ‘Better’ therefore depends on the question, and the evidence is weak.
What is BPC-157 arginate?
It is a salt of the unchanged BPC-157 peptide (GEPPPGKPADDAGLV) with L-arginine as counter-ion. Diagen’s patent prefers the 1:2 di-L-arginine salt, abbreviated Arg-BPC, made by adding excess arginine, back-titrating to pH 7.40 with acetic acid, and purifying by reversed-phase chromatography.
Is pentadeca arginate the same as BPC-157 arginate?
Not necessarily. ‘Pentadeca arginate’ is a marketing name with no registry definition. Some sellers use it for Arg-BPC and others for altered sequences. Only a stated sequence plus a salt-form assay tells you what the material is.
Is BPC-157 acetate a different molecule?
No. It is the same peptide with acetate counter-ions. FDA’s GSRS registers BPC-157 acetate as a mono-acetate, C62H98N16O22·C2H4O2, MW 1479.59.
Is BPC-157 arginate really 1000 times more stable?
No such figure appears in the patent. It comes from dividing 84.9% by 0.08% remaining at one time point (pH 3, 5 h). That comparison is likely confounded by pH, because the arginine salt adds base to an unbuffered medium.
Does BPC-157 arginate have higher oral bioavailability?
No study has compared the oral absorption of the arginate and the acetate. Published pharmacokinetics cover injected peptide in rats and dogs. One oral formulation patent reported plasma levels for the arginate alone, without a comparator or intravenous reference.
Why does an arginate vial contain less peptide?
Arginine weighs about 174 g/mol, so two of them add about 348 g/mol to a 1419.6 g/mol peptide. By our calculation an ideal 1:2 arginate is about 80% peptide by mass, versus about 96% for an ideal mono-acetate, before water.
How can I tell which salt form I have?
Use counter-ion assays. Amino acid analysis shows arginine, which is not part of the BPC-157 sequence, and gives its ratio. Ion chromatography or NMR quantifies acetate or TFA. Karl Fischer measures water. The pH of a 1% solution is a quick screen: about 3.9 for acetate and about 7.4 for a 1:2 arginate. HPLC purity and mass spectrometry alone do not establish the salt.
Is BPC-157 stable in gastric juice?
Sources conflict. Sikirić’s group reports BPC-157 as stable in human gastric juice for over 24 hours. Diagen’s patent reports rapid loss of the acetate in artificial gastric juice with pepsin at pH 2–3. The conditions differ and neither has been independently replicated.
Related reading
- What is BPC-157?
- Peptide identity: sequences, fragments, modifications and salt forms
- GHK-Cu salt forms
- How to read a peptide COA
About the authors: This explainer was written by the SaiyanMed Research Team. It is based on full-text reading of the cited patents, registry records and peer-reviewed papers. Every sourced figure links to its reference. Values we derived ourselves are labelled as calculations, with the method shown. Last updated: 2026-10-29.
References
- Diagen d.o.o. (inventor R. Ručman). WO2014142764A1, New stable pentadecapeptide salts… Published 2014-09-18. Examples 1–5, Tables 1–6, HPLC method.
- Diagen d.o.o. US 9,850,282 B2, Stable pentadecapeptide salts… Filed 2013-05-09, granted 2017-12-26. Granted claim 1 covers SEQ ID NO 1 · 2 basic amino acids.
- Sikirić P. et al. US 6,288,028 B1, BPC peptide salts with organo-protective activity… Granted 2001-09-11.
- U.S. FDA Global Substance Registration System (GSRS): BPC-157 ACETATE, C62H98N16O22·C2H4O2, MW 1479.59.
- Sikora K. et al. The role of counter-ions in peptides: an overview. Pharmaceuticals 2020;13:442. doi:10.3390/ph13120442
- Wang X. et al. Purity determination of synthetic glucagon using a mass balance approach. Sci Rep 2020;10:4423. doi:10.1038/s41598-020-61109-9
- Sikirić P. et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011.
- Sikirić P. et al. The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity… Pharmaceuticals 2024;17:461.
- Sikirić P. et al. Stable gastric pentadecapeptide BPC 157 as a therapy and safety key… Pharmaceuticals 2025;18:928.
- He L. et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157… Front Pharmacol 2022;13:1026182.
- Majewski F. EP4226918A1, Pharmaceutical single dosage form for oral delivery of peptides. Published 2023-08-16.
- Piper D.W., Fenton B.H. pH stability and activity curves of pepsin with special reference to their clinical importance. Gut 1965;6:506–508.
- PubChem: L-Arginine (CID 6322).
- Vasireddi N., Hahamyan H., et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 2025.
Research Use Only Disclaimer
This article is a chemistry and analytical-science explainer. It is not medical advice, and it is not a protocol for administration, a dosing reference, or a claim about any effect in people or animals. Studies are described for scientific context only. Materials discussed are for in-vitro laboratory research use only.